A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Recruiting

Phase 1

ALN-APPA Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Sponsor:

Alnylam Pharmaceuticals

Code:

NCT05231785

Conditions

Early-Onset Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ALN-APP

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-02. This information was provided to ClinicalTrials.gov by Alnylam Pharmaceuticals on 2025-08-26.